Exemestane: one option of several
111 studies: a test or a strategy chooses among drugs. Page 2 of 2. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCompletedNCT02549430Phase 2Report a problem
- Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCompletedNCT02511639Phase 3Report a problem
- Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2Report a problem
- Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast CancerCompletedNCT01654185Phase 2Report a problem
- DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsCompletedNCT01619111Phase 3Report a problem
- Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCompletedNCT01553903Phase 4Report a problem
- Pharmacology of Adjuvant Hormonotherapy in Breast CancerCompletedNCT01127295Phase 4Report a problem
- Dendritic Cell Based Therapy for Breast Cancer PatientsWithdrawnNCT00935558Phase 2Report a problem
- Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast CancerTerminatedNCT00684216Phase 2/3Report a problem
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast CancerCompletedNCT00508586Phase 1Report a problem
- Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical TrialCompletedNCT00354302Phase 3Report a problem